Trials / Completed
CompletedNCT03419364
Study of Nicotinamide in Early Onset Preeclampsia
Phase II Study of Nicotinamide in Early Onset Preeclampsia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- University of North Carolina, Chapel Hill · Academic / Other
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect on maternal blood pressure in women with early onset preeclampsia and to determine peak and trough levels of nicotinamide. We will compare peak and trough levels in healthy non-pregnant and healthy pregnant participants.
Detailed description
See brief summary above
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nicotinamide | 2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday |
Timeline
- Start date
- 2017-11-01
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
- First posted
- 2018-02-01
- Last updated
- 2022-09-08
- Results posted
- 2022-09-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03419364. Inclusion in this directory is not an endorsement.